Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807929 | 1.00 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL4804204 | 0.84 | MEN1 (0.41) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL4807594 | 0.84 | MEN1 (0.41) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL4804207 | 0.84 | MEN1 (0.41) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL28563227 | 0.83 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL28557184 | 0.83 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL10509033 | 0.83 | CYP2C19 (0.44) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL10507262 | 0.83 | CYP2C19 (0.44) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL10507825 | 0.83 | CYP2C19 (0.44) | SLC1A3SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL10507303 | 0.83 | CYP2C19 (0.44) | SLC1A3SLC1A2SLC1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2133342-A1 | PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR, PREPARATION METHODS AND USES THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2009-12-16 | — | — | EP | disclosed |
| US-7446125-B2 | Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders | UNIVERSIDAD DEL PAIS VASCO (ES) | 2008-11-04 | — | — | US | disclosed |
| US-20060211630-A1 | Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders | UNIVERSIDAD DEL PAIS VASCO (ES) | 2006-09-21 | — | — | US | disclosed |
| CN-1033584-C | Benzo-fused lactams that promote release of growth hormone | MERCK & CO INC (US) | 1996-12-18 | — | — | CN | disclosed |
| EP-0513974-B1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO INC (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5310737-A | Benzo-fused lactams that promote the release of growth hormone | MERCK & CO., INC. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5206235-A | Animal growth regulators; stimulants | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0513974-A1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| CN-1066070-A | Promote the new benzo-fused lactams that tethelin discharges | MERCK & CO INC (US) | 1992-11-11 | — | — | CN | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-4107183-A | Synthesis of optically active carboxylic acid esters | HOFFMANN-LA ROCHE INC. (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211630-A1 | Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders | ITGB5, ITGA5, ITGAV | SLC1A3 2824/4885SLC1A2 2967/4885SLC1A1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.